<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02179047</url>
  </required_header>
  <id_info>
    <org_study_id>TCHIRB-1030509-E</org_study_id>
    <nct_id>NCT02179047</nct_id>
  </id_info>
  <brief_title>Correlational Study on the Biomarkers Application to the Prediction and Diagnosis of Cardiovascular Diseases</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taipei City Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taipei City Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Through the literature review , we pick out a series of forward-looking biological indicators
      as follows :

        1. NGAL

        2. Cystatin C:

        3. Galectin-3:

        4. Copeptin:

        5. MR-Pro ANP:

        6. sST2:
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1) NGAL (Neutrophil Gelatinase Associated Lipocalin): in the cardiovascular system , NGAL and
      endothelial cell apoptosis , atherosclerosis , and abdominal aortic aneurysm associated with
      thrombosis of a relationship. Heart and kidney complications in common a number of studies
      have demonstrated that NGAL in acute heart failure , cardiac catheterization / angiography
      management, and diagnostic usefulness of acute coronary artery disease and heart surgery ,
      and how to make NGAL may pathological processes in the cardiovascular play a role. In the
      past studies have also demonstrated in sepsis (sepsis), cardiopulmonary around to support
      cardiac surgery, caused by acute renal developer injury and renal transplant patients and
      other studies confirm this early detection of serum creatinine more acute kidney injury . So
      we tried to make the results in this study .

      (2) Cystatin C: Chronic kidney disease is a cardiovascular morbidity and mortality risk and a
      significant global health problem. Has been used to estimate renal function , serum
      creatinine, can be used instead . In several studies have shown to be more sensitive than
      that for predicting eGFRcreat serum creatinine or adverse events. This parameter also showed
      greater diagnostic sensitivity for the detection of mild renal damage . Cystatin C and
      metabolic syndrome and cardiovascular risk factors is also a correlation study confirmed (M.
      Magnusson et.al, 2013). Therefore , Cystatin C is emerging as a new biomarker for
      cardiovascular disease.

      (3) Galectin-3: has proven to be a marker of myocardial fibrosis, Lars Gullestad , who in
      2012 also found that Galectin-3 is mainly predictive of ischemic etiology . elderly patients
      with systolic heart failure death. And approved by the U.S. Food and Drug Administration to
      help in the prognosis of patients with heart failure in 2011 . Research has also pointed out
      that , Galectin-3 and there is a positive correlation between renal injury , and the
      correlation is not affected by whether the patients suffering from heart failure while
      affected.

      (4) Copeptin: Copeptin was considered non -specific stress response of the marker , and may
      also have been proposed various non- cardiovascular monitoring and early warning and
      cardiovascular diseases ( coronary artery disease, heart failure and acute ) , etc., in a
      previous study , including patients with acute myocardial infarction was found with Copeptin
      related , and there Copeptin associated left ventricular ejection fraction (LVEF), and also
      the follow-up patients found to have a direct correlation with left ventricular volume, and
      is considered poor prognostic factor of death.

      (5) MR-Pro ANP (midregional-Pro atrial natriuretic peptide): discovery and diagnosis of heart
      failure can be predicted in 1984, is a major discovery in the field of biological indicators
      of heart , but also a milestone, Elif Elmas et al found that when the 2011 MR-Pro ANP in
      patients suffering from cardiovascular disease as a diagnosis of myocardial fibrosis new
      biological indicators. Past research has also pointed out that can be used to predict lower
      respiratory tract infections and pneumonia, long and short-term mortality, Alzheimer's
      disease, and can diagnose sepsis and bacterial shock and prognosis prediction .

      (6) sST2 (somatostatin2): Excessive sST2 may cause abnormal cardiac hypertrophy , fibrosis,
      and heart failure . Clinically, symptoms of heart failure with a high concentration of the
      patients diagnosed with sST2 severity determined correlations to predict increased risk of
      complications. Past research indicates measured values sST2 patients suffering from
      cardiovascular disease increased Jie phenomenon, and found that the measured values sST
      severity of cardiovascular disease 2 was positively correlated, has now been approved for use
      in patients with cardiovascular disease and new biomarkers predictive value of heart failure
      and death , but for the progress of heart failure severity change , changes in the measured
      value for sST2 correlation someone has not been confirmed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Biomarker Titer of Patients With Coronary Artery Disease</measure>
    <time_frame>6-12 months</time_frame>
    <description>The titer of 6 biomarkers(NGAL,Cystatin C,Galectin-3,Copeptin,MR-Pro ANP,sST2).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Biomarker of Healthy Subjects(Placebo)</measure>
    <time_frame>6-12 months</time_frame>
    <description>The relationship of 6 biomarkers(NGAL,Cystatin C,Galectin-3,Copeptin,MR-Pro ANP,sST2) of healthy subjects(placebo).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SYNTAX(SYNergy Between Percutaneous Coronary Intervention With TAXus) for Stable Angina Receveived Coronary Angiogram</measure>
    <time_frame>6-12 months</time_frame>
    <description>The relationship of 6 biomarkers(NGAL,Cystatin C,Galectin-3,Copeptin,MR-Pro ANP,sST2) with SYNTAX score.
The SYNTAX Score is a unique tool to score complexity of coronary artery disease; there is no theoretical range existed for the SYNTAX score.
Low risk:&lt;22; intermediate risk: 22-33, high risk:&gt;33</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">214</enrollment>
  <condition>Stable Angina</condition>
  <arm_group>
    <arm_group_label>stable angina, biomarker</arm_group_label>
    <description>patients with stable angina who received coronary angiography.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <description>healthy subject</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>coronary angiography</intervention_name>
    <description>percutaneous coronary intervention. coronary angiography.</description>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_label>stable angina, biomarker</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      ELISA kit for Human Galectin-3 Quantikine ELISA Kit (R&amp;D system, Minneapolis, Mn)、Human
      ST2/IL-1 R4 Quantikine ELISA Kit(R&amp;D system, Minneapolis, Mn)、Human Cystatin C Quantikine
      ELISA Kit(R&amp;D system, Minneapolis, Mn)、 Human Lipocalin-2/NGAL Quantikine ELISA Kit(R&amp;D
      system, Minneapolis, Mn)、Human midregional pro-atrial natriuretic peptide(MR-proANP) ELISA
      Kit(Cusabio, China, Cn)、Soluble ST2/IL-1R4 (HUMAN) Elisa Kit(AvisceraBioscience, Santa
      Clara,Ca)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patients with stable angina who received coronary angiography.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  stable angina who eligible for coronary angiography after non-invasive stress test.

        Exclusion Criteria:

          -  intolerance to procedure or contarst medium.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Taipei City Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>May 27, 2014</study_first_submitted>
  <study_first_submitted_qc>June 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2014</study_first_posted>
  <results_first_submitted>November 10, 2017</results_first_submitted>
  <results_first_submitted_qc>February 21, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 25, 2020</results_first_posted>
  <last_update_submitted>February 21, 2020</last_update_submitted>
  <last_update_submitted_qc>February 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Taipei City Hospital</investigator_affiliation>
    <investigator_full_name>Yueh-Chung, Chen</investigator_full_name>
    <investigator_title>chief of ICU</investigator_title>
  </responsible_party>
  <keyword>SYNTAX ,NGAL,Cystatin C,Galectin-3,Copeptin.MR-ProANP,sST2.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angina, Stable</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Intervention</title>
          <description>patients with stable angina who received coronary angiography and percutaneous coronary intervention.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>healthy subjects</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="194"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="187"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Stable Angina</title>
          <description>receive coronary angiogram</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>healthy subjects</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="187"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="207"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="137"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="151"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" spread="14"/>
                    <measurement group_id="B2" value="60" spread="12"/>
                    <measurement group_id="B3" value="61" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="137"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="187"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Biomarker Titer of Patients With Coronary Artery Disease</title>
        <description>The titer of 6 biomarkers(NGAL,Cystatin C,Galectin-3,Copeptin,MR-Pro ANP,sST2).</description>
        <time_frame>6-12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NGAL</title>
            <description>biomarker</description>
          </group>
          <group group_id="O2">
            <title>Cystatin C</title>
            <description>biomarker</description>
          </group>
          <group group_id="O3">
            <title>Galectin-3</title>
            <description>biomarker</description>
          </group>
          <group group_id="O4">
            <title>Copeptin</title>
            <description>biomarker</description>
          </group>
          <group group_id="O5">
            <title>MR-Pro ANP</title>
            <description>biomarker</description>
          </group>
          <group group_id="O6">
            <title>sST2</title>
            <description>biomarker</description>
          </group>
        </group_list>
        <measure>
          <title>Biomarker Titer of Patients With Coronary Artery Disease</title>
          <description>The titer of 6 biomarkers(NGAL,Cystatin C,Galectin-3,Copeptin,MR-Pro ANP,sST2).</description>
          <units>tilter</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="187"/>
                <count group_id="O2" value="187"/>
                <count group_id="O3" value="187"/>
                <count group_id="O4" value="187"/>
                <count group_id="O5" value="187"/>
                <count group_id="O6" value="187"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="187"/>
                <count group_id="O2" value="187"/>
                <count group_id="O3" value="187"/>
                <count group_id="O4" value="187"/>
                <count group_id="O5" value="187"/>
                <count group_id="O6" value="187"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="2" upper_limit="36"/>
                    <measurement group_id="O2" value="5" lower_limit="0" upper_limit="10"/>
                    <measurement group_id="O3" value="60" lower_limit="1" upper_limit="120"/>
                    <measurement group_id="O4" value="0.5" lower_limit="0.024" upper_limit="0.76"/>
                    <measurement group_id="O5" value="0.16" lower_limit="0.008" upper_limit="0.26"/>
                    <measurement group_id="O6" value="184" lower_limit="9" upper_limit="218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>ANOVA</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.02</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Biomarker of Healthy Subjects(Placebo)</title>
        <description>The relationship of 6 biomarkers(NGAL,Cystatin C,Galectin-3,Copeptin,MR-Pro ANP,sST2) of healthy subjects(placebo).</description>
        <time_frame>6-12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NGAL</title>
            <description>biomarker</description>
          </group>
          <group group_id="O2">
            <title>Cystatin C</title>
            <description>biomarker</description>
          </group>
          <group group_id="O3">
            <title>Galectin-3</title>
            <description>biomarker</description>
          </group>
          <group group_id="O4">
            <title>Copeptin</title>
            <description>biomarker</description>
          </group>
          <group group_id="O5">
            <title>MR-Pro ANP</title>
            <description>biomarker</description>
          </group>
          <group group_id="O6">
            <title>sST2</title>
            <description>biomarker</description>
          </group>
        </group_list>
        <measure>
          <title>Biomarker of Healthy Subjects(Placebo)</title>
          <description>The relationship of 6 biomarkers(NGAL,Cystatin C,Galectin-3,Copeptin,MR-Pro ANP,sST2) of healthy subjects(placebo).</description>
          <units>tilter</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="20"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="1" upper_limit="34"/>
                    <measurement group_id="O2" value="4" lower_limit="1" upper_limit="12"/>
                    <measurement group_id="O3" value="52" lower_limit="2" upper_limit="82"/>
                    <measurement group_id="O4" value="0.1" lower_limit="0.01" upper_limit="0.4"/>
                    <measurement group_id="O5" value="0.12" lower_limit="0.09" upper_limit="0.83"/>
                    <measurement group_id="O6" value="121" lower_limit="68" upper_limit="178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>ANOVA</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.05</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.005</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>SYNTAX(SYNergy Between Percutaneous Coronary Intervention With TAXus) for Stable Angina Receveived Coronary Angiogram</title>
        <description>The relationship of 6 biomarkers(NGAL,Cystatin C,Galectin-3,Copeptin,MR-Pro ANP,sST2) with SYNTAX score.
The SYNTAX Score is a unique tool to score complexity of coronary artery disease; there is no theoretical range existed for the SYNTAX score.
Low risk:&lt;22; intermediate risk: 22-33, high risk:&gt;33</description>
        <time_frame>6-12 months</time_frame>
        <population>The SYNTAX Score is a unique tool to score complexity of coronary artery disease; there is no theoretical range existed for the SYNTAX score.
SYNTAX Web site: http://www.syntaxscore.com/index.php Low risk:&lt;22; intermediate risk: 22-33, high risk:&gt;33</population>
        <group_list>
          <group group_id="O1">
            <title>NGAL</title>
            <description>patients with stable angina who received coronary angiography.</description>
          </group>
          <group group_id="O2">
            <title>Cystatin C</title>
            <description>patients with stable angina who received coronary angiography.</description>
          </group>
          <group group_id="O3">
            <title>Galectin-3</title>
            <description>patients with stable angina who received coronary angiography.</description>
          </group>
          <group group_id="O4">
            <title>Copeptin</title>
            <description>patients with stable angina who received coronary angiography.</description>
          </group>
          <group group_id="O5">
            <title>MR-Pro ANP</title>
            <description>patients with stable angina who received coronary angiography.</description>
          </group>
          <group group_id="O6">
            <title>sST2</title>
            <description>patients with stable angina who received coronary angiography.</description>
          </group>
          <group group_id="O7">
            <title>Placebo(Healthy Subjects)</title>
            <description>patients without stable angina who received coronary angiography.</description>
          </group>
        </group_list>
        <measure>
          <title>SYNTAX(SYNergy Between Percutaneous Coronary Intervention With TAXus) for Stable Angina Receveived Coronary Angiogram</title>
          <description>The relationship of 6 biomarkers(NGAL,Cystatin C,Galectin-3,Copeptin,MR-Pro ANP,sST2) with SYNTAX score.
The SYNTAX Score is a unique tool to score complexity of coronary artery disease; there is no theoretical range existed for the SYNTAX score.
Low risk:&lt;22; intermediate risk: 22-33, high risk:&gt;33</description>
          <population>The SYNTAX Score is a unique tool to score complexity of coronary artery disease; there is no theoretical range existed for the SYNTAX score.
SYNTAX Web site: http://www.syntaxscore.com/index.php Low risk:&lt;22; intermediate risk: 22-33, high risk:&gt;33</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="187"/>
                <count group_id="O2" value="187"/>
                <count group_id="O3" value="187"/>
                <count group_id="O4" value="187"/>
                <count group_id="O5" value="187"/>
                <count group_id="O6" value="187"/>
                <count group_id="O7" value="187"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="187"/>
                <count group_id="O2" value="187"/>
                <count group_id="O3" value="187"/>
                <count group_id="O4" value="187"/>
                <count group_id="O5" value="187"/>
                <count group_id="O6" value="187"/>
                <count group_id="O7" value="187"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22" spread="8"/>
                    <measurement group_id="O2" value="19" spread="4"/>
                    <measurement group_id="O3" value="32" spread="8"/>
                    <measurement group_id="O4" value="28" spread="13"/>
                    <measurement group_id="O5" value="33" spread="15"/>
                    <measurement group_id="O6" value="19" spread="3"/>
                    <measurement group_id="O7" value="6" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.39</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.005</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Intervention</title>
          <description>patients with worsen of angina symptoms after percutaneous coronary intervention.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>patients with worsen of angina symptoms after percutaneous coronary intervention.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>chen yueh-chung</name_or_title>
      <organization>taipei city hospital</organization>
      <phone>88627093600 ext 3741</phone>
      <email>chenyuehchung.tw@yahoo.com.tw</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

